CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.